Hylvastam

Sodium Hydrogen Carbonate, the active ingredient in Hylvastam, is a buffering agent presented as an injectable solution for intravenous use. It helps correct acid‑base disturbances and is employed in clinical settings to manage metabolic acidosis, cardiac arrest, and certain drug toxicities. The compound works by increasing plasma bicarbonate concentration, thereby raising blood pH and supporting cardiovascular stability.

GNH USA supplies Hylvastam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Hylvastam is used intravenously to address conditions involving acid‑base imbalance and cardiac emergencies. - Metabolic Acidosis: restores normal pH by supplying bicarbonate ions. - Cardiac Arrest: improves myocardial contractility and vascular tone during resuscitation. - Hyperkalemia: facilitates intracellular shift of potassium as part of emergency management. - Drug Overdose (e.g., tricyclic antidepressants): mitigates toxicity by alkalinizing plasma and urine.

Intravenous sodium bicarbonate may cause a range of adverse reactions.

Common Side Effects: - Hypernatremia: elevated serum sodium levels. - Metabolic Alkalosis: excessive rise in blood pH. - Fluid Overload: risk of volume expansion. - Hypokalemia: lowered serum potassium. - Increased CO2 Production: may exacerbate respiratory compromise. - Local Infusion Site Irritation: pain or phlebitis at the catheter site.

Serious or Rare Side Effects: - Severe Alkalosis: can lead to neuromuscular irritability or seizures. - Pulmonary Edema: especially in patients with heart failure. - Cardiac Arrhythmias: due to electrolyte shifts. - Paradoxical Intracellular Acidosis: in specific metabolic conditions. - Severe Hypernatremia: may cause neurologic dysfunction. - Anaphylactoid Reactions: rare hypersensitivity to the solution.

When using Hylvastam, clinicians should observe several safety measures. - Renal Function: monitor closely in patients with impaired kidney function. - Cardiac Status: assess before administration in heart failure or arrhythmia risk. - Electrolyte Balance: check serum sodium and potassium levels prior to and during therapy. - Acid‑Base Status: avoid in patients already alkalotic. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Sodium Hydrogen Carbonate can affect the pharmacokinetics of several medications.

Major Interactions (Avoid): - Acid‑dependent antibiotics (e.g., penicillins, tetracyclines): reduced absorption and efficacy. - Lithium: increased serum lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., ACE inhibitors): may enhance hypotensive effects. - Digoxin: altered serum levels due to changes in electrolyte balance. - NSAIDs: potential for increased sodium and water retention. - Warfarin: possible alteration of INR values requiring closer monitoring.